Commercial Novartis shares fall as Entresto sales weaken PharmaphorumNovartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.CardiovascularRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026. Cardiovascular Read full story Post navigation Previous: Seaport and Hemab target $180m IPOs as biotech listings accumulateNext: Merck KGaA and Remepy join forces to develop combo drug-digital therapies Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
